BioNTech advances Phase 3 trial of pumitamig with Gilead drug in triple-negative breast cancer
BNTX•BioNTech advanced a Phase 3 trial of pumitamig combined with Gilead’s sacituzumab govitecan for triple-negative breast cancer.
BNTX•BNTX•BNTX•BioNTech advanced a Phase 3 trial of pumitamig combined with Gilead’s sacituzumab govitecan for triple-negative breast cancer.
BioNTech advanced a Phase 3 trial of pumitamig combined with Gilead’s sacituzumab govitecan for triple-negative breast cancer.
